A simple, selective, and stability-indicating reverse phase liquid chromatographic method has been developed and validated for the simultaneous determination of impurities and forced degradation products of quetiapine fumarate. The chromatographic separation was achieved on Inertsil-3 C8, 150 mm × 4.6 mm, 5 μm column at 35°C with UV detection at 217 nm using gradient mobile phase at a flow rate of 1.0 mL/min. Mobile phase A contains a mixture of 0.01 M di-potassium hydrogen orthophosphate (pH 6.8) and acetonitrile in the ratio of 80:20 (v/v), respectively, and mobile phase B contains a mixture of 0.01 M di-potassium hydrogen orthophosphate (pH 6.8) and acetonitrile in the ratio of 20:80 (v/v), respectively. The drug product was subjected to the stress conditions of oxidative, hydrolysis (acid and base), hydrolytic, thermal, and photolytic degradation. Quetiapine fumarate was found to degrade significantly in acid, base, and oxidative stress conditions. The degradation products were well resolved from main peak and its impurities. The mass balance was found to be in the range of 96.6–102.2% in all the stressed conditions, thus proved the stability-indicating power of the method. The developed method was validated as per ICH guidelines with respect to specificity, linearity, limit of detection and quantification, accuracy, precision, and robustness.
[1]. J.G. Small S.R. Hirsch L.A. Arvanitis B.G. Miller C.G. Link 1997 Arch. Gen. Psychiatry 54 549.
[3]. N. Rajendraprasad K. Basavaiah K. B. Vinay 2010 J. Pre-Clin. Clin. Res. 4 24.
[4]. K. Basavaiah N. Rajendraprasad P.J. Ramesh K.B. Vinay 2010 Thai J. Pharm. Sci. 34 146.
[5]. S.R. Dhaneshwar N.G. Patre M.V. Mahadik 2009 Acta Chromatogr. 21 83.
[6]. B. Dhandapani A. Somasundaram S.H. Raseed M. Raja K. Dhanabal 2009 Int. J. PharmTech Res. 1 139.
[7]. S.A. Jadhav S.B. Landge S.S. Shelke N.C. Niphade R.K. Panchangam V.T. Mathad S. R. Bembalkar 2010 Chromatographia 71 1055.
[8]. D. Suneetha A.L. Rao 2010 E-J. Chem. 7 261.
[9]. S. Hillaert L. Snoeck W. Van den Bossche 2004 J. Chromatogr. A 1033 357.
[10]. N. El-Enany A. El-Brashy F. Belal N. El-Bahay 2009 Port. Electrochim. Acta 27 113.
[11]. L. Mercolini M. Grillo C. Bartoletti G. Boncompagni M.A. Raggi 2007 Anal. Bioanal. Chem. 388 235.
[12]. F. Belal A. Elbrashy M. Eid J.J. Nasr 2008 J. Liq. Chromatogr. Relat. Technol. 31 1283.
[13]. P.C. Davis O. Bravo M. Gehrke C.T. Azumaya 2010 J. Pharm. Biomed. Anal. 51 1113.
[14]. R. Mandrioli S. Fanali A. Ferranti M.A. Raggi 2002 J. Pharm. Biomed. Anal. 30 969.
[15]. Z. Zhou X. Li K. Li Z. Xie Z. Cheng W. Peng F. Wang R. Zhu H. Li 2004 J. Chromatogr. B 802 257.
[16]. E.U. Stolarczyk L. Kaczmarek K. Eksanow M. Kubiszewski M. Glice A. Kutner 2009 Pharm. Dev. Technol. 14 27.
[17]. H. Xu D. Wang C. Sun Y. Pan M. Zhou 2007 J. Pharm. Biomed. Anal. 44 414.
[18]. Ch. Bharathi K.J. Prabahar Ch.S. Prasad M.S. Rao G.N. Trinadhachary V.K. Handa R. Dandala A. Naidu 2008 Pharmazie 63 14.
[19]. V. Mittapelli L. Vadali D.A. Sivalakshmi M.V. Suryanarayana 2010 Rasayan J. Chem. 3 677.
[20]. R.K. Trivedi M.C. Patel 2011 Sci. Pharm. 79 97.
[21]. S.R. Krishna B.M. Rao N.S. Rao 2008 Rasayan J. Chem. 1 466.
[22]. M. Bakshi S. Singh 2002 J. Pharm. Biomed. Anal. 28 1011.
[23]. ICH Q1A (R2), Stability Testing of New Drug Substances and Products, 2000.
[24]. ICH Q1B, Photostability testing on new drug substances and products, 1996.
[25]. ICH Q2 (R1), Validation of Analytical Procedures: Text and Methodology, 2005.